Based in Japan and India. Has led to 1 successful fundraise in Japan. Been working the space of Venture Capital and Private Equity for the last 3 years.

Avail Medsystems, a leading medical technology company in the field of telemedicine for the Procedural TelemedicineTM, today announced that it has raised $100 million in Series B funding under the leadership of D1 Capital Partners, with participation from 8VC and existing investors. Avail has previously raised $25 million in Series A and Series A-1 funding from investors including Lux Capital, Coatue, Sonder Capital, Playground Global, Baidu Ventures and Refactor Capital.

The Avail System consists of a portable console used by surgeons in the operating room, coupled with a versatile app for experts providing remote guidance on the procedure. The technology was developed over a three-year period by a team with over 400 years of combined medical technology development, sales and marketing experience. While a remarkable advance for caregivers and patients, traditional telemedicine systems lack the capabilities needed in the operating rooms where patients are most vulnerable. Avail’s Procedural TelemedicineTM system is designed specifically for the operating room and enables surgeons, external experts and the healthcare ecosystem to better serve patients by providing the right knowledge, at the right time, to the right people.

Avail Medsystems is a pioneering medical technology company that removes barriers to in-person collaboration in the field of medical procedures. With a customer-centric business model, Avail’s purpose-built Procedural TelemedicineTM technology digitalizes physical presence and enables on-the-go, HIPAA-compliant collaboration between a network of healthcare professionals and industry experts.

Please note that this piece of work originally appeared in English at As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at

Leave a Reply

Your email address will not be published. Required fields are marked *